

February 20, 2025



Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology

MINNEAPOLIS, Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with industry-leading sensitivity and specificity, the Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species.

Representing the most referenced spatial biology technology in the industry, RNAscope provides an unprecedented single-cell view of disease pathology and therapeutic response across a wide range of diseases.

Backed by the [RNAscope probe guarantee](#), this new addition to the large and growing RNAscope probe menu enables customers to easily accelerate validation of new RNA biomarkers from single-cell genomics and spatial discovery programs. Available for purchase on [bio-techne.com](https://www.bio-techne.com), customers can easily select RNAscope probes together with R&D Systems antibodies to further illuminate changes in cell phenotypes and functional states. With ready-to-use manual and automated formats available for each RNAscope probe, including for use on the automated [Lunaphore COMET™](#) system, researchers can seamlessly advance new RNA and multiomic biomarkers from late discovery to translational research or clinical assay development using the same RNAscope probe design.

"Empowering our customers with precise and scalable solutions to advance translational research and precision medicine is central to our mission," said Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "With over 12,000 citations in clinical and translational research combined, our expanded portfolio of gold-standard RNAscope probes enables customers to accelerate biomarker validation and ultimately improve lives."

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately \$1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <http://www.bio-techne.com> or follow the Company on social media at [Facebook](#), [LinkedIn](#), [Twitter](#) or [YouTube](#).

[About Bio-Techne Corporation](#) (NASDAQ: TECH)

Contact: David Clair, Vice President, Investor Relations & Corporate Development

david.clair@bio-techne.com

612-656-4416



View original content to download multimedia: <https://www.prnewswire.com/news-releases/bio-techne-launches-expanded-menu-of-rnascope-probes-for-human-and-mouse-transcriptome-to-advance-spatial-biology-302380023.html>

SOURCE Bio-Techne Corporation